Develops immunotherapeutic options to treat chronic and infectious diseases of relevance. It is currently focused on the development of a low cost, personalized, potentially safe and effective immunotherapy, named ConvitVax, targeted to underprivileged patients with breast cancer. This therapy seeks to boost the patient’s own immune system against the malignant cells by combining the patient’s own tumor cells with BCG and low concentrations of formalin. Studies in animals and a human pilot experience show that the combination of these components stimulate the immune system, achieving an effective and specific response against the body’s tumor cells, with minimal to no side-effects and a possible establishment of immune memory, which may reduce the possibility of disease recurrence.
Through partnerships with research and health centers, JCWO works to advance its clinical trials in the US, South America and Europe using the ConvitVax.
We aim to make immunotherapies available to patients who do not have access to new innovative therapies and in some cases, to standard of care treatments
Go through our history
Doctor Convit performs a successful culture of the mycobacteria in the armadillo and makes the final production of a specific immunotherapy (therapeutic vaccine) in combination with BCG to treat patients with leprosy.
Describes similarities between leprosy and leishmaniasis based on clinical, immunological, and pathological aspects.